Trial results

Effect of LIXIsenatide on the Renal System

NCT02276196 on ClinicalTrials.gov · last registry update 2016-04-29

Finished April 2016, after enrolling 40 people. lixisenatide is approved in the US, but not for diabetes and diabetic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P4

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Amsterdam UMC, location VUmc

Sponsor type

Other

Enrollment

40

Started

2014-09

Primary completion

2016-04 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF)

Conditions studied

Diabetic Kidney Disease · Diabetic Nephropathy · Diabetes Mellitus · Glucagon-Like Peptide 1

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.